TY - JOUR
T1 - Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer
AU - Amankwah, Ernest K
AU - Kelemen, Linda E
AU - Wang, Qinggang
AU - Song, Honglin
AU - Chenevix-Trench, Georgia
AU - Beesley, Jonathan
AU - Webb, Penelope M
AU - Pearce, Celeste L
AU - Wu, Anna H
AU - Pike, Malcolm C
AU - Stram, Daniel O
AU - Chang-Claude, Jenny
AU - Wang-Gohrke, Shan
AU - Ness, Roberta B
AU - Goode, Ellen L
AU - Cunningham, Julie M
AU - Fridley, Brooke L
AU - Vierkant, Robert A
AU - Tworoger, Shelley S
AU - Whittemore, Alice S
AU - McGuire, Valerie
AU - Sieh, Weiva
AU - Gayther, Simon A
AU - Gentry-Maharaj, Aleksandra
AU - Menon, Usha
AU - Ramus, Susan J
AU - Rossing, Mary Anne
AU - Doherty, Jennifer A
AU - Goodman, Marc T
AU - Carney, Michael E
AU - Lurie, Galina
AU - Wilkens, Lynne R
AU - Kjær, Susanne Krüger
AU - Høgdall, Estrid
AU - Cramer, Daniel W
AU - Terry, Kathryn L
AU - Garcia-Closas, Montserrat
AU - Yang, Hannah
AU - Lissowska, Jolanta
AU - Anton-Culver, Hoda
AU - Ziogas, Argyrios
AU - Schildkraut, Joellen M
AU - Berchuck, Andrew
AU - Pharoah, Paul D P
AU - on behalf of the Australian Ovarian Cancer Study Group
PY - 2011/5/1
Y1 - 2011/5/1
N2 - Background: We previously reported an association between rs2660753, a prostate cancer susceptibility polymorphism, and invasive epithelial ovarian cancer (EOC; OR = 1.2, 95% CI= 1.0-1.4, Ptrend = 0.01) that showed a stronger association with the serous histological subtype (OR = 1.3, 95% CI = 1.1-1.5, Ptrend = 0.003). Methods: We sought to replicate this association in 12 other studies comprising 4,482 cases and 6,894 controls of white non-Hispanic ancestry in the Ovarian Cancer Association Consortium. Results: No evidence for an association with all cancers or serous cancers was observed in a combined analysis of data from the replication studies (all: OR = 1.0, 95% CI = 0.9-1.1, Ptrend = 0.61; serous: OR = 1.0, 95% CI = 0.9-1.1, Ptrend = 0.85) or from the combined analysis of discovery and replication studies (all: OR = 1.0, 95% CI = 1.0-1.1, Ptrend = 0.28; serous: OR = 1.1, 95% CI = 1.0-1.2, Ptrend = 0.11). There was no evidence for statistical heterogeneity in ORs across the studies. Conclusions: Although rs2660753 is a strong prostate cancer susceptibility polymorphism, the association with another hormonally related cancer, invasive EOC, is not supported by this replication study. Impact: Our findings, based on a larger sample size, emphasize the importance of replicating potentially promising genetic risk associations.
AB - Background: We previously reported an association between rs2660753, a prostate cancer susceptibility polymorphism, and invasive epithelial ovarian cancer (EOC; OR = 1.2, 95% CI= 1.0-1.4, Ptrend = 0.01) that showed a stronger association with the serous histological subtype (OR = 1.3, 95% CI = 1.1-1.5, Ptrend = 0.003). Methods: We sought to replicate this association in 12 other studies comprising 4,482 cases and 6,894 controls of white non-Hispanic ancestry in the Ovarian Cancer Association Consortium. Results: No evidence for an association with all cancers or serous cancers was observed in a combined analysis of data from the replication studies (all: OR = 1.0, 95% CI = 0.9-1.1, Ptrend = 0.61; serous: OR = 1.0, 95% CI = 0.9-1.1, Ptrend = 0.85) or from the combined analysis of discovery and replication studies (all: OR = 1.0, 95% CI = 1.0-1.1, Ptrend = 0.28; serous: OR = 1.1, 95% CI = 1.0-1.2, Ptrend = 0.11). There was no evidence for statistical heterogeneity in ORs across the studies. Conclusions: Although rs2660753 is a strong prostate cancer susceptibility polymorphism, the association with another hormonally related cancer, invasive EOC, is not supported by this replication study. Impact: Our findings, based on a larger sample size, emphasize the importance of replicating potentially promising genetic risk associations.
U2 - http://dx.doi.org/10.1158/1055-9965.EPI-11-0053
DO - http://dx.doi.org/10.1158/1055-9965.EPI-11-0053
M3 - Journal article
SN - 1055-9965
VL - 20
SP - 1028
EP - 1031
JO - Cancer Epidemiology, Biomarkers & Prevention
JF - Cancer Epidemiology, Biomarkers & Prevention
IS - 5
ER -